AC Immune SA
NASDAQ:ACIU 11:01:59 AM EDT
| Market Cap (Intraday) | 241.04M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.51 |
| 50-Day MA | $3.12 |
| 200-Day MA | $3.23 |
AC Immune SA Stock, NASDAQ:ACIU
EPFL Innovation Park, Building B, Lausanne, Vaud 1015
Switzerland
Phone: +41.21.345.91.21
Number of Employees: 161
Description
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.